GT Biopharma Reports Director and Officer Changes
Ticker: GTBP · Form: 8-K · Filed: Sep 16, 2024 · CIK: 109657
Sentiment: neutral
Topics: management-change, governance, officer-appointment
TL;DR
GT Biopharma shakes up board and execs, new faces coming.
AI Summary
GT Biopharma, Inc. filed an 8-K on September 16, 2024, reporting changes in its board of directors and certain officers, as well as updates to compensatory arrangements. The filing details the election of new directors and potential changes in executive roles, impacting the company's governance structure.
Why It Matters
Changes in a company's board and executive team can signal shifts in strategy, operational focus, or financial direction, potentially affecting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensatory arrangements can introduce uncertainty regarding future strategy and execution, warranting closer monitoring.
Key Players & Entities
- GT Biopharma, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- September 16, 2024 (date) — Date of Report
FAQ
What specific changes were made to the board of directors?
The filing indicates the election of directors, but specific names and the exact number of changes are detailed within the document's sections on director appointments.
Were there any changes in executive officer positions?
Yes, the filing covers the appointment of certain officers, suggesting potential shifts in executive roles.
What is the nature of the updates to compensatory arrangements?
The filing mentions updates to compensatory arrangements for certain officers, the specifics of which would be elaborated in the relevant sections of the report.
When was this report filed with the SEC?
This Form 8-K was filed on September 16, 2024.
What is the primary business of GT Biopharma, Inc.?
GT Biopharma, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
Filing Stats: 429 words · 2 min read · ~1 pages · Grade level 12.9 · Accepted 2024-09-16 16:05:21
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value GTBP The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 29KB
- 0001493152-24-036381.txt ( ) — 191KB
- gtbp-20240916.xsd (EX-101.SCH) — 3KB
- gtbp-20240916_lab.xml (EX-101.LAB) — 33KB
- gtbp-20240916_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GT BIOPHARMA, INC. Date: September 16, 2024 By: /s/ Alan Urban Alan Urban Chief Financial Officer